CytoMed Therapeutics (NASDAQ:GDTC) Trading Down 6% – Here’s Why

CytoMed Therapeutics Limited (NASDAQ:GDTC) shares traded down 6% during trading on Friday . The company traded as low as $0.93 and last traded at $0.9301. Approximately 26,738 shares were traded during trading, a decline of 87% from the average session volume of 201,908 shares. The stock had previously closed at $0.9894.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CytoMed Therapeutics in a research note on Wednesday, July 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

CytoMed Therapeutics Trading Down 6.0%

The company has a fifty day moving average of $1.04 and a 200 day moving average of $1.02. The company has a current ratio of 5.17, a quick ratio of 5.17 and a debt-to-equity ratio of 0.06.

Insider Activity

In other news, Director Chee Kong Choo purchased 112,000 shares of the stock in a transaction dated Wednesday, May 13th. The shares were bought at an average cost of $1.15 per share, for a total transaction of $128,800.00. Following the transaction, the director owned 430,324 shares in the company, valued at $494,872.60. This trade represents a 35.18% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.